



Oto Therapeutics

Mission



Oto Therapeutics identifies novel medication for hearing disorders with primary focus on tinnitus

Business focus



Oto Therapeutics has novel and unique non clinical screening platforms that allows the identification of novel medicines. These platforms cover pharmacology and drug safety.

Clinical research is focussed on the identification of subpopulations of patients with tinnitus, on translational science facilitating the R&D process and on design and execution of proof concept studies in human.

The company



- Spin off of the University Hospital of Antwerp/University of Antwerp
- Founded by
 - Prof. Dr. Paul Van de Heyning
 - Dean of Faculty of Medicine
 - Head of the department of ORL
 - www.ua.ac.be/main.aspx?c=paul.vandeheyning
 - Prof. Dr. Didier de Chaffoy
 - Former head of Research and Early Development for J&J Pharma Division in Europe
 - Faculty of Medicine at University of Hasselt
 - CFO: Mr. Vic Maes
 - Former Director Finance at Janssen Pharmaceutica, Belgium
 - Former Head of Business Support for J&J Pharma RED division Europe